» Articles » PMID: 38686351

Clinical Significance of Uncommon, Non-Clinical, and Novel Autoantibodies

Overview
Publisher Dove Medical Press
Date 2024 Apr 30
PMID 38686351
Authors
Affiliations
Soon will be listed here.
Abstract

Autoantibodies are a common mark of autoimmune reaction and their identification in the patients' serum, cerebrospinal fluid, or tissues is generally believed to represent diagnostic or prognostic biomarkers of autoimmune diseases or autoinflammatory conditions. Traditionally, autoantibody testing is an important part of the clinical examination of suspected patients, and in the absence of reliable T cell tests, characterization of autoantibody responses might be suitable in finding causes of specific autoimmune responses, their strength, and sometimes commencement of autoimmune disease. Autoantibodies are also useful for prognostic stratification in clinically diverse groups of patients if checked repeatedly. Antibody discoveries are continuing, with important consequences for verifying autoimmune mechanisms, diagnostic feasibility, and clinical management. Adding newly identified autoantibody-autoantigen pairs to common clinical laboratory panels should help upgrade and harmonize the identification of systemic autoimmune rheumatic disorders and other autoimmune conditions. Herein, we aim to summarize our current knowledge of uncommon and novel autoantibodies in the context of discussing their validation, diagnostic practicability, and clinical relevance. The regular updates within the field are important and well justified.

Citing Articles

The Emerging Role of Immunoglobulins and Complement in the Stimulation of Neuronal Activity and Repair: Not as Simple as We Thought.

Veremeyko T, Barteneva N, Vorobyev I, Ponomarev E Biomolecules. 2024; 14(10).

PMID: 39456256 PMC: 11506258. DOI: 10.3390/biom14101323.

References
1.
Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C . Haemolytic uraemic syndrome. Lancet. 2017; 390(10095):681-696. DOI: 10.1016/S0140-6736(17)30062-4. View

2.
He S, Lin Y . In vitro stimulation of C1s proteolytic activities by C1s-presenting autoantibodies from patients with systemic lupus erythematosus. J Immunol. 1998; 160(9):4641-7. View

3.
Buckley C, Oger J, Clover L, Tuzun E, Carpenter K, Jackson M . Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol. 2001; 50(1):73-8. DOI: 10.1002/ana.1097. View

4.
Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J . Antinuclear antibodies giving the 'multiple nuclear dots' or the 'rim-like/membranous' patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther. 2007; 24(11-12):1575-83. DOI: 10.1111/j.1365-2036.2006.03172.x. View

5.
Liu C, Kao A, Manzi S, Ahearn J . Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis. 2013; 5(4):210-33. PMC: 3728979. DOI: 10.1177/1759720X13485503. View